Grace Therapeutics, Inc.
GRCE
$3.02
$0.072.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.20M | 7.29M | 7.07M | 6.68M | 7.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.70M | 16.04M | 13.30M | 11.31M | 12.26M |
| Operating Income | -16.70M | -16.04M | -13.30M | -11.31M | -12.26M |
| Income Before Tax | -16.44M | -14.28M | -13.71M | -14.69M | -48.59M |
| Income Tax Expenses | -3.07M | -2.67M | -2.27M | -1.83M | -9.81M |
| Earnings from Continuing Operations | -13.37 | -11.61 | -11.45 | -12.85 | -38.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.37M | -11.61M | -11.45M | -12.85M | -38.77M |
| EBIT | -16.70M | -16.04M | -13.30M | -11.31M | -12.26M |
| EBITDA | -16.70M | -16.04M | -13.30M | -11.30M | -12.24M |
| EPS Basic | -1.17 | -1.02 | -1.16 | -1.46 | -5.06 |
| Normalized Basic EPS | -0.90 | -0.78 | -0.86 | -0.90 | -1.02 |
| EPS Diluted | -1.17 | -1.02 | -1.16 | -1.46 | -5.06 |
| Normalized Diluted EPS | -0.90 | -0.78 | -0.86 | -0.90 | -1.02 |
| Average Basic Shares Outstanding | 45.43M | 45.43M | 41.48M | 37.99M | 33.99M |
| Average Diluted Shares Outstanding | 45.43M | 45.43M | 41.48M | 37.99M | 33.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |